Phosphodiesterase Inhibitors
1 drugsAbout Phosphodiesterase
Phosphodiesterases (PDEs) are enzymes that regulate intracellular signaling by hydrolyzing phosphodiester bonds in cyclic nucleotides like cAMP and cGMP. These cyclic nucleotides act as second messengers, and PDEs control the duration and intensity of cellular responses. PDEs are attractive targets for drug development due to their involvement in key signaling pathways.
Currently, there is no genetic evidence available linking phosphodiesterases to specific diseases. However, the established role of PDEs in regulating key cellular functions suggests that modulating their activity could have therapeutic benefits.
There is one FDA-approved drug, ASPIRIN AND DIPYRIDAMOLE, that targets phosphodiesterases. This drug, approved in 2009, is a small molecule used in the cardiovascular therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Antiplatelet Drugs with only 4 trials.
- phase3 represents biological uncertainty with 59% completion.
Top Phosphodiesterase Drugs
AMNEAL PHARMS is the only company with an approved drug targeting phosphodiesterases.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's druggability.
Phosphodiesterase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Phosphodiesterase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage.
Phosphodiesterase Clinical Trials 513 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 68 | 57 | 3 | 6 | 95% |
| Phase 2 | 104 | 66 | 17 | 20 | 80% |
| Phase 3 | 125 | 54 | 22 | 49 | 71% |
| Phase 4 | 216 | 123 | 28 | 63 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phosphodiesterase Drug Approval Timeline (2009 - 2009)
The first and only drug, ASPIRIN AND DIPYRIDAMOLE, was approved in 2009.
The lack of recent approvals suggests potential saturation or challenges in developing new PDE-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 6 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 338 clinical trials targeting Phosphodiesterase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities